Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368408 | 0.80 | LMNA (0.62) | ALDH1A1LMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL2368765 | 0.79 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL2368393 | 0.75 | ALDH1A1 (0.56) | ALDH1A1LMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL14964981 | 0.75 | LMNA (0.65) | LMNAMAPTSMN1; SMN2HPGDKDM4E | |
| SCHEMBL23579792 | 0.74 | MAPT (0.78) | ALDH1A1LMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL2368269 | 0.74 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL2369123 | 0.74 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL2368688 | 0.74 | FGFR1 (0.40) | ALDH1A1LMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL1502695 | 0.74 | KCNA5 (0.53) | ALDH1A1MAPTNPC1RAB9AKDM4E | |
| SCHEMBL14965090 | 0.73 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022076-B2 | Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents | XENTION LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| EP-1641803-B3 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-12-08 | — | — | EP | disclosed |
| EP-1641803-B1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| CN-1823071-A | Thienopyrimidine derivatives as potassium channel inhibitors | XENTION DISCOVERY LTD (GB) | 2006-08-23 | — | — | CN | disclosed |
| EP-1641803-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026935-A1 | Compounds | XENTION DISCOVERY LTD. | 2005-02-03 | — | — | US | disclosed |
| WO-2004111057-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026935-A1 | Compounds | KCNJ11, KCNJ1, KCNH1 | ALDH1A1 247/4885LMNA 1126/4885MAPT 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.